AU2021292458A1 - Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting - Google Patents

Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting Download PDF

Info

Publication number
AU2021292458A1
AU2021292458A1 AU2021292458A AU2021292458A AU2021292458A1 AU 2021292458 A1 AU2021292458 A1 AU 2021292458A1 AU 2021292458 A AU2021292458 A AU 2021292458A AU 2021292458 A AU2021292458 A AU 2021292458A AU 2021292458 A1 AU2021292458 A1 AU 2021292458A1
Authority
AU
Australia
Prior art keywords
subject
chosen
cancer
selectin
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021292458A
Other languages
English (en)
Inventor
William E. Fogler
John L. Magnani
Theodore Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of AU2021292458A1 publication Critical patent/AU2021292458A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2021292458A 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting Abandoned AU2021292458A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063038856P 2020-06-14 2020-06-14
US63/038,856 2020-06-14
US202063060605P 2020-08-03 2020-08-03
US63/060,605 2020-08-03
US202063198856P 2020-11-17 2020-11-17
US63/198,856 2020-11-17
PCT/US2021/036992 WO2021257398A1 (en) 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Publications (1)

Publication Number Publication Date
AU2021292458A1 true AU2021292458A1 (en) 2023-01-19

Family

ID=76731129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021292458A Abandoned AU2021292458A1 (en) 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Country Status (12)

Country Link
US (1) US20230218649A1 (https=)
EP (1) EP4164655A1 (https=)
JP (1) JP2023529485A (https=)
KR (1) KR20230024402A (https=)
CN (1) CN116033907A (https=)
AU (1) AU2021292458A1 (https=)
BR (1) BR112022025480A2 (https=)
CA (1) CA3181278A1 (https=)
IL (1) IL298977A (https=)
MX (1) MX2022015894A (https=)
WO (1) WO2021257398A1 (https=)
ZA (1) ZA202213322B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250100273A (ko) * 2023-12-26 2025-07-03 서울대학교병원 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
KR102055958B1 (ko) * 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
WO2015048616A1 (en) * 2013-09-30 2015-04-02 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20200171005A9 (en) 2015-12-02 2020-06-04 Glycomimetics, Inc. Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
JP7275131B2 (ja) * 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR20200128025A (ko) * 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020219419A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
JP2022529806A (ja) 2019-04-24 2022-06-24 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
US20220265691A1 (en) 2019-07-12 2022-08-25 Glycomimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types

Also Published As

Publication number Publication date
WO2021257398A1 (en) 2021-12-23
CN116033907A (zh) 2023-04-28
CA3181278A1 (en) 2021-12-23
EP4164655A1 (en) 2023-04-19
BR112022025480A2 (pt) 2023-01-17
MX2022015894A (es) 2023-01-24
ZA202213322B (en) 2024-04-24
KR20230024402A (ko) 2023-02-20
US20230218649A1 (en) 2023-07-13
IL298977A (en) 2023-02-01
JP2023529485A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
Yawata et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells
Mueller et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer
Shi et al. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
Huang et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia
Xia et al. Angiogenic factors in chronic lymphocytic leukemia
CN102088983A (zh) 利用选择的糖模拟化合物的血液癌症的治疗
Hou et al. Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression
KR102413412B1 (ko) 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도
US20110195924A1 (en) Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
EP4164655A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
Zhang et al. Galectin-9 promotes colon cancer development by polarizing macrophages toward the M2 phenotype
US20250152731A1 (en) Anti-trop2 antibody combination therapies and methods of use thereof
EP3731853A1 (en) Method for treating breast cancer and chronic diseases
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
WO2011088402A2 (en) The use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
JP2023527411A (ja) がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法
US9351981B2 (en) Use of PKC-iota inhibitors for the treatment of breast cancer
Pegoraro The P2X7 receptor modulates extracellular ATP levels cell to cell communication and chemoresistance in oncogenesis
De Gouveia Cardiac glycosides, a novel treatment for neuroblastoma: efficacy and mechanism
WO2025172617A1 (en) Compositions and methods for the treatment and/or prevention of an ilc2 rich cancer
Wiernik Diagnosis and treatment of adult acute myeloid leukemia other than acute promyelocytic leukemia
Sądej et al. Session 17. Tumor Microenvironment in Cancer Progression
Xu Tumor cell survival strategies in Hodgkin lymphoma

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period